David Hysong and SHEPHERD Therapeutics

Ananth   Raman; John   Masko; Aldo  Sesia

Case | HBS Case Collection | November 2018

David Hysong and SHEPHERD Therapeutics

by Ananth Raman, John Masko and Aldo Sesia

Abstract

In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his and other rare cancers. Two years later, the company had several drugs in promising stages of development but were at least 3 to 5 years away from commercialization, if they made it through clinical trials successfully. Only about 4% of drugs that enter clinical trials receive U.S. FDA approval. It is October 2018, and Shepherd is running out of money. Hysong needs to raise $5 million to fund operations for 2019 and at least $20 million for the following few years. But the company is too early to attract the type of venture capital he needs. Even if he got financing, Hysong worried that the company’s mission could be compromised by investors more interested in a return on their investment than saving lives, and he worried about the scaling challenges ahead.

Keywords: cancer; therapeutics; drugs; Health Care and Treatment; Business Startups; Product Development; Financing and Loans; Growth and Development Strategy; Problems and Challenges;

Language: English

Format: Print

24 pages

Educators

Citation:

Raman, Ananth, John Masko, and Aldo Sesia. "David Hysong and SHEPHERD Therapeutics." Harvard Business School Case 619-012, November 2018.

During the 1980s, President Ronald Reagan and his administration instituted several far-reaching economic policies that had both near- and long-term impacts on such aspects of the U.S. economy as monetary policy, inflation, the tax structure, and the role of government. While observers were divided on whether specific policies yielded positive or negative outcomes, one particular area where Reagan’s legacy was debated was the extent to which his administration’s actions contributed to growing levels of inequality in the country.

In 2018, the Hollywood film industry is facing tough headwinds. Fewer and fewer Americans are going to movie theaters, opting instead to watch movies on demand in the comfort of their own homes or on portable devices. Adam Aron, the head of the world’s largest movie theater chain, AMC Entertainment, is employing an aggressive strategy to bolster the moviegoing experience by adding new amenities including plush reclining seats, reserved seating, and upscale food and beverage options. He is also placing a special emphasis on expansion overseas where the market is growing. Will his actions allow the company to successfully compete in a mature industry under assault by new digital competitors? With the growing popularity of entertainment subscription services like Netflix and Spotify, should AMC adopt a similar business model?

Faculty & Research

David Hysong and SHEPHERD Therapeutics

Abstract

Citation:

About the Author

More from the Author